Newer Blood Thinner Brilinta Exceeds Plavix For Cardiac Bypass Surgery Patients.
In a hassle comparing two anti-clotting drugs, patients given Brilinta before cardiac skirt surgery were less proper to die than those given Plavix, researchers found weight. Both drugs preclude platelets from clumping and forming clots, but Plavix, the more popular drug, has been linked to potentially risky side effects in cancer patients.
In addition, some people don't metabolize it well, making it less effective capsule. "We did pay the way for about a 50 percent reduction in mortality in these patients, who took Brilinta, but without any better in bleeding complications," Dr Claes Held, an associate professor of cardiology at the Uppsala Clinical Research Center at Uppsala University in Sweden and the study's show the way researcher, said during an afternoon mash conference Tuesday.
So "Ticagrelor (Brilinta) in this setting, with acute coronary syndrome patients with the imminent need for bypass surgery, is more effective than clopidogrel (Plavix) in preventing cardiovascular and compute mortality without increasing the risk of bleeding" vimax extender ipod. A danger with any anti-platelet painkiller is the risk of uncontrolled bleeding, which is why these drugs are stopped before patients undergo surgery.
Held was scheduled to baksheesh the results Tuesday at the American College of Cardiology's annual meeting in Atlanta. For the study, Held and colleagues looked at a subgroup of 1261 patients in the Platelet Inhibition and Patient Outcomes (PLATO) trial. The researchers found that 10,5 percent of the patients given Brilinta with an increment of aspirin before surgery had a resolution attack, fondle or died from heart disease within a week after surgery. Among patients given Plavix added to aspirin, 12,6 percent had the same adverse outcomes.
Patients taking Brilinta had a aggregate death rate of 4,6 percent, compared with 9,2 percent for patients taking Plavix. In addition, the cardiovascular obliteration rates were 4 percent among patients taking Brilinta and 7,5 percent amidst those taking Plavix. When Held's team looked at each group individually, they found no statistically significant modification for heart attack and stroke and no significant difference in major bleeding from the bypass operation itself. The two drugs knead in different ways.
Plavix needs the body to convert it to an active form, which poses some problems. Last week, the US Food and Drug Administration required Bristol-Myers Squibb and Sanofi Aventis, the makers of Plavix, to sum a "black box" indication to the drug's label, alerting doctors and patients that some patients cannot fully transmute the drug, so it may be less effective for them. Brilinta, which is in a strange class of drugs, does not rely on metabolic conversion, so it acts faster and clears the body faster than Plavix. This enables quicker recapture of normal platelet function, the researchers say.
But Held can't delineate the difference in the rate of death. "That's the billion dollar question. Right now we don't interpret the mechanism. We see the difference in mortality, but we cannot disclose it in differences in bleeding so there has to be some other effect explaining the difference".
The PLATO study was funded by AstraZeneca, the maker of Brilinta. Results of another writing-room presented at the meeting Tuesday found that the drug Tekturna (aliskiren) given to patients after a marrow attack did not improve heart function as researchers had hoped.
In that trial - called the Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) - Tekturna, which blocks the hormone renin, was given to patients along with common blood pressure-lowering drugs. But the researchers found it provided no additional service in callousness function and only served to raise potassium levels and cause low blood pressure.
So "Morbidity and mortality last high in patients following heart attack, with a substantial or slue of patients subsequently developing heart failure," Dr Scott D Solomon, pilot of noninvasive cardiology at the Brigham and Women's Hospital, Harvard Medical School in Boston and guide researcher, said in a statement. "We hoped that this study would generate the information needed to procedure a major morbidity and mortality trial.
However, our results show that the addition of aliskiren to standard therapy in high-risk post-MI patients does not sham left ventricular size or function licorice urdu meaning. These findings suggest the trouble for caution when treating post-heart attack patients".
